RespireRx Pharmaceuticals Inc.
RSPI · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $87 | $98 | $98 | $29 |
| G&A Expenses | $245 | $368 | $292 | $192 |
| SG&A Expenses | $245 | $368 | $292 | $192 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $333 | $466 | $390 | $221 |
| Operating Income | -$333 | -$466 | -$390 | -$221 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$63 | -$215 | -$40 | -$69 |
| Pre-Tax Income | -$396 | -$681 | -$430 | -$290 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$396 | -$681 | -$430 | -$317 |
| % Margin | – | – | – | – |
| EPS | -0.002 | -0.004 | -0.003 | -0.003 |
| % Growth | 62.5% | -29% | -24% | – |
| EPS Diluted | -0.002 | -0.004 | -0.003 | -0.003 |
| Weighted Avg Shares Out | 267,733 | 168,214 | 137,182 | 125,544 |
| Weighted Avg Shares Out Dil | 267,733 | 168,214 | 137,182 | 125,544 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $73 | $225 | $67 | $70 |
| Depreciation & Amortization | $256 | $466 | $28 | $221 |
| EBITDA | -$77 | $10 | -$335 | $1 |
| % Margin | – | – | – | – |